CN111925340A - Preparation process of methyl mercapto thiadiazole - Google Patents
Preparation process of methyl mercapto thiadiazole Download PDFInfo
- Publication number
- CN111925340A CN111925340A CN201911287812.8A CN201911287812A CN111925340A CN 111925340 A CN111925340 A CN 111925340A CN 201911287812 A CN201911287812 A CN 201911287812A CN 111925340 A CN111925340 A CN 111925340A
- Authority
- CN
- China
- Prior art keywords
- temperature
- mmtd
- hdf
- acid
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- QPYXMRZUQWAHDP-UHFFFAOYSA-N 5-methylthiadiazole-4-thiol Chemical compound CC=1SN=NC=1S QPYXMRZUQWAHDP-UHFFFAOYSA-N 0.000 title abstract description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- KPULRXFDAIJSEP-UHFFFAOYSA-N 4-methylsulfanylthiadiazole Chemical compound CSC1=CSN=N1 KPULRXFDAIJSEP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims abstract description 14
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims abstract description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012043 crude product Substances 0.000 claims abstract description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 10
- 239000003377 acid catalyst Substances 0.000 claims abstract description 9
- YNNGZCVDIREDDK-UHFFFAOYSA-N aminocarbamodithioic acid Chemical compound NNC(S)=S YNNGZCVDIREDDK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000012362 glacial acetic acid Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims 5
- 238000007363 ring formation reaction Methods 0.000 abstract description 10
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 208000012839 conversion disease Diseases 0.000 abstract description 2
- 238000007670 refining Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 cefkaempferia Chemical compound 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention discloses a preparation process of methyl mercapto thiadiazole, which relates to the technical field of pharmaceutical chemicals, and comprises the following steps of (1) preparing hydrazino dithioformic acid (HDF) by taking hydrazine hydrate as a raw material and reacting with carbon disulfide; (2) the HDF and acetic acid are cyclized under the action of an acid catalyst to generate a crude product of methylmercaptothiadiazole (MMTD); (3) refining to obtain the MMTD product. Compared with the traditional process, the process greatly reduces or even avoids the use of concentrated sulfuric acid, is green and pollution-free, has simple process steps, greatly improves the cyclization reaction rate and the cyclization reaction conversion rate, saves time and energy, and is suitable for industrial production.
Description
Technical Field
The invention relates to the technical field of pharmaceutical chemicals, and particularly relates to a preparation process of methylmercaptothiadiazole.
Background
The methylmercaptothiadiazole is an important intermediate for producing cefazolin, cefkaempferia, cefazedone, azone cephalosporin, cefprozil, cephalosporin BL-S339, furbenconazole cephalosporin and the like, and is clinically and widely used because the medicaments have the characteristics of broad antibacterial spectrum, good absorption, small side effect, particular suitability for oral absorption and the like.
The prior preparation process of the methyl mercapto thiadiazole is to obtain ethyl acetate through hydrazine, addition and cyclization, and comprises the following specific steps: carrying out reflux reaction on hydrazine hydrate and ethyl acetate for 5 hours to obtain acethydrazide; adding acethydrazide into an ethanol solution of potassium hydroxide or ammonia gas, dropwise adding carbon disulfide at low temperature, reacting for 3h, filtering, and leaching to obtain potassium acethydrazide dithioformate or ammonium salt; adding the dried potassium salt or ammonium salt into low-temperature concentrated sulfuric acid for cyclization, adding the cyclization mother liquor into a large amount of ice water, separating out a crude product of the methylmercaptothiadiazole, and refining to obtain a finished product.
The most important defects of the reaction are that a large amount of concentrated sulfuric acid is used in the cyclization reaction, a large amount of waste acid is generated, great pressure is generated on equipment and environment protection, and the relevant patents do not describe how the generated waste acid is treated, which is a great leak.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a preparation process of methylmercaptothiadiazole, which bypasses the traditional route of using a large amount of concentrated sulfuric acid, greatly reduces or even avoids the use of the concentrated sulfuric acid, is green and pollution-free, has simple process steps, greatly improves the cyclization reaction rate, improves the cyclization reaction conversion rate, saves time and energy, and is suitable for industrial production.
The preparation process of the methylmercaptothiadiazole comprises the following steps:
1. adding 1mol of hydrazine hydrate into a reaction bottle, dropwise adding carbon disulfide with the molar weight 1-1.05 times of that of the hydrazine hydrate at the temperature of 20-25 ℃, wherein the dropwise adding time is 2-3 hours, after the dropwise adding is finished, preserving the heat at the temperature of 20-25 ℃ for 1-2 hours, filtering to obtain hydrazino dithioformic acid (HDF), and performing vacuum drying on the HDF at the temperature of 55-75 ℃ for more than 3 hours to control the water content to be less than 0.1% to obtain white or light yellow crystalline powder;
2. controlling the temperature to be 25-30 ℃, adding dried HDF into a reaction bottle, adding 1-1.1mol of glacial acetic acid, dropwise adding an acid catalyst for 1-2h, heating to react for 3-5 h, cooling to 0-5 ℃, adjusting the pH of a 30% sodium hydroxide solution to 8-9, and filtering to obtain a crude product of the methylmercaptothiadiazole (MMTD);
3. adding the MMTD crude product into distilled water with the weight ratio of 5-7 times, heating and refluxing for 0.5-1 h, slowly cooling to 45-50 ℃, stirring for 1-2h, continuously cooling to 0-5 ℃, stirring for 0.5-1 h, filtering to obtain an MMTD wet product, vacuum drying for 2h at 55-60 ℃, heating to 70-75 ℃ for more than 2h, and controlling the water content to be less than 0.1% to obtain white crystalline powder.
In the step 1, the mass fraction of hydrazine hydrate is 80%.
In the step 1, the vacuum degree is 0.09-0.1 MPa.
In the step 2, the acid catalyst may be one of concentrated hydrochloric acid, concentrated sulfuric acid, and phosphorus oxychloride.
In the step 2, the amount of the acid catalyst is 1-1.5 times of the molar weight of hydrazine hydrate.
In the step 2, the temperature rise reaction temperature is 50-70 ℃.
In the step 3, the reflux temperature is 90-95 ℃.
In the step 3, the vacuum degree is 0.09-0.1 MPa.
Compared with the prior art, the invention has the following beneficial effects:
1. the raw materials are wide in source, the reaction condition is mild, the selectivity is high, the industrial production is easy, and the production advantage is achieved;
2. the operation steps are simple, various cheap and easily available raw materials are used, and the cost advantage is achieved;
3. the acid catalyst is used in the cyclization step, so that the selectivity is high, the yield can reach over 95 percent, and the selectivity advantage is achieved;
4. the process avoids a reaction system in which a large amount of concentrated sulfuric acid is used for cyclization in the traditional process, greatly reduces the use amount of the concentrated sulfuric acid, even can avoid the use of the concentrated sulfuric acid, further reduces and avoids the generation of waste acid, is a green synthesis route, and has the advantage of environmental protection.
In conclusion, the research has stronger innovation and practicability.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1
A preparation process of methylmercaptothiadiazole comprises the following steps:
(1) putting 62.5g of 80% hydrazine hydrate into a three-neck flask, controlling the reaction temperature to be 25 ℃, dropwise adding 80g of carbon disulfide for 2 hours, keeping the temperature at 25 ℃ for 1 hour, filtering, and vacuum drying HDF wet products at 55 ℃ for 4 hours to obtain white crystalline powder;
(2) controlling the temperature to be 30 ℃, adding dried HDF into a reaction bottle, adding 61.2g of glacial acetic acid, dropwise adding 122g of 36% concentrated hydrochloric acid for 2h, heating to 50 ℃, reacting for 3h, cooling to 0-5 ℃, adjusting the pH value to 8.5 by using 30% sodium hydroxide solution, and filtering to obtain a crude product of the methylmercaptothiadiazole (MMTD);
(3) adding the MMTD crude product into 750g of distilled water, heating to 90 ℃, refluxing for 1h, slowly cooling to 45 ℃, stirring for 1h, continuously cooling to 0-5 ℃, stirring for 1h, filtering to obtain an MMTD wet product, vacuum drying for 2h at 55 ℃, heating to 70 ℃ for 3h, controlling the water content to be less than 0.1%, and obtaining 125.8g of white crystalline powder, the yield is 95.3%, and the purity is 99.2%.
Example 2
A preparation process of methylmercaptothiadiazole comprises the following steps:
(1) putting 62.5g of 80% hydrazine hydrate into a three-neck flask, controlling the reaction temperature to be 25 ℃, dropwise adding 80g of carbon disulfide for 2 hours, keeping the temperature at 25 ℃ for 1 hour, filtering, and vacuum drying HDF wet products at 55 ℃ for 4 hours to obtain white crystalline powder;
(2) controlling the temperature to be 25 ℃, adding dried HDF into a reaction bottle, adding 61.2g of glacial acetic acid, dropwise adding 199g of phosphorus oxychloride for 2h, heating to 60 ℃, reacting for 3h, cooling to 0-5 ℃, adjusting the pH value to 8.5 by using 30% sodium hydroxide solution, and filtering to obtain a crude product of methylmercaptothiadiazole (MMTD);
(3) adding the MMTD crude product into 800g of distilled water, heating to 95 ℃, refluxing for 1h, slowly cooling to 45 ℃, stirring for 1h, continuously cooling to 0-5 ℃, stirring for 1h, filtering to obtain an MMTD wet product, vacuum drying for 2h at 55 ℃, heating to 70 ℃ for 3h, controlling the water content to be less than 0.1%, and obtaining 122.1g of white crystalline powder, wherein the yield is 92.5%, and the purity is 99.5%.
Example 3
A preparation process of methylmercaptothiadiazole comprises the following steps:
(1) putting 62.5g of 80% hydrazine hydrate into a three-neck flask, controlling the reaction temperature to be 25 ℃, dropwise adding 80g of carbon disulfide for 2 hours, keeping the temperature at 25 ℃ for 1 hour, filtering, and vacuum drying HDF wet products at 55 ℃ for 4 hours to obtain white crystalline powder;
(2) controlling the temperature to be 25 ℃, adding dried HDF into a reaction bottle, adding 61.2g of glacial acetic acid, dropwise adding 107.8g of 98% concentrated sulfuric acid, wherein the dropwise adding time is 1.5h, heating to 60 ℃, reacting for 3h, cooling to 0-5 ℃, adjusting the pH value to 8.5 by using 30% sodium hydroxide solution, and filtering to obtain a crude product of the methylmercaptothiadiazole (MMTD);
(3) adding the MMTD crude product into 800g of distilled water, heating to 95 ℃, refluxing for 1h, slowly cooling to 45 ℃, stirring for 1h, continuously cooling to 0-5 ℃, stirring for 1h, filtering to obtain an MMTD wet product, vacuum drying for 2h at 55 ℃, heating to 70 ℃ for 3h, controlling the water content to be less than 0.1%, and obtaining 123.4g of white crystalline powder, wherein the yield is 93.5%, and the purity is 99.3%.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (9)
1. A preparation process of methylmercaptothiadiazole is characterized by comprising the following steps:
1) adding hydrazine hydrate into a reaction container, dropwise adding carbon disulfide with the molar weight 1-1.05 times that of the hydrazine hydrate, preserving the heat at 20-25 ℃ for 1-2h, filtering to obtain hydrazino dithioformic acid (HDF), and drying the HDF in vacuum to control the water content of the HDF to be less than 0.1%;
2) controlling the temperature to be 25-30 ℃, adding dried HDF into a reaction bottle, adding glacial acetic acid with the molar weight 1-1.1 times that of hydrazine hydrate, dropwise adding an acid catalyst, heating for reaction, cooling to 0-5 ℃, adjusting the pH to 8-9, and filtering to obtain a crude product of methylmercaptothiadiazole (MMTD);
3) adding the MMTD crude product into distilled water in an amount which is 5-7 times the weight of the MMTD crude product, heating and refluxing, then slowly cooling to 45-50 ℃, stirring for 1-2 hours, continuously cooling to 0-5 ℃, stirring for 0.5-1 hour, filtering to obtain an MMTD wet product, and drying in vacuum to control the water content to be less than 0.1% to obtain white crystalline powder.
2. The method of claim 1, wherein: the mass fraction of the hydrazine hydrate is 80%.
3. The method of claim 1, wherein: the dripping time of the carbon disulfide is 2-3h, and the dripping temperature is 20-25 ℃.
4. The method of claim 1, wherein: the vacuum degree of the vacuum drying in the step 1) is 0.09-0.1MPa, the drying temperature is 55-75 ℃, and the drying time is more than 3 h.
5. The method of claim 1, wherein: the vacuum drying in the step 3) is specifically that the drying is carried out for more than 2 hours at the temperature of 55-60 ℃ and then for more than 2 hours at the temperature of 70-75 ℃ under the condition that the vacuum degree is 0.09-0.1MPa
The method of claim 1, wherein: the acid catalyst comprises more than one of concentrated hydrochloric acid, concentrated sulfuric acid and phosphorus oxychloride.
6. The method of claim 1, wherein: the molar weight of the acid catalyst is 1-1.5 times of that of hydrazine hydrate, and the dripping time of the acid catalyst is 1-2 h.
7. The method of claim 1, wherein: the temperature rise temperature of the step 2) and the step 3) is 50-70 ℃.
8. The method of claim 1, wherein: the reflux temperature is 90-95 ℃.
9. The method of claim 1, wherein: the pH adjusting solution was a 30% sodium hydroxide solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911287812.8A CN111925340A (en) | 2019-12-16 | 2019-12-16 | Preparation process of methyl mercapto thiadiazole |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911287812.8A CN111925340A (en) | 2019-12-16 | 2019-12-16 | Preparation process of methyl mercapto thiadiazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111925340A true CN111925340A (en) | 2020-11-13 |
Family
ID=73282760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911287812.8A Pending CN111925340A (en) | 2019-12-16 | 2019-12-16 | Preparation process of methyl mercapto thiadiazole |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111925340A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114380770A (en) * | 2021-12-24 | 2022-04-22 | 山东艾孚特科技有限公司 | Synthesis process of methyl mercapto thiadiazole catalyzed by solid superacid |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3838432A1 (en) * | 1988-11-12 | 1990-05-17 | Bayer Ag | 2,5-DISUBSTITUTED 1,3,4-THIADIAZOLE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN PEST CONTROL |
| CN1221740A (en) * | 1997-12-12 | 1999-07-07 | 美国拜尔公司 | Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate |
| CN1948295A (en) * | 2005-10-11 | 2007-04-18 | 四川贝力克生物技术有限责任公司 | Preparation method of 5-(2-phenyl)-2-mercapto-1,3,4-thiadiazole |
| CN102775370A (en) * | 2011-05-11 | 2012-11-14 | 中国科学院海洋研究所 | Thiazole compound, its preparation and application |
| CN103145645A (en) * | 2013-03-18 | 2013-06-12 | 陆宏庆 | Preparation technology of mercapto-5-methyl-1,3,4-thiadiazole |
| CN103360337A (en) * | 2013-07-11 | 2013-10-23 | 浙江海蓝化工有限公司 | Preparation method of 2-sulfydryl-5-methyl-1, 3, 4-thiadiazole |
| CN107721948A (en) * | 2017-11-16 | 2018-02-23 | 江苏绿叶农化有限公司 | A kind of preparation method of flufenacet |
| WO2019234651A1 (en) * | 2018-06-06 | 2019-12-12 | Isagro S.P.A. | Process for the preparation of thiadiazole derivatives |
-
2019
- 2019-12-16 CN CN201911287812.8A patent/CN111925340A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3838432A1 (en) * | 1988-11-12 | 1990-05-17 | Bayer Ag | 2,5-DISUBSTITUTED 1,3,4-THIADIAZOLE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN PEST CONTROL |
| CN1221740A (en) * | 1997-12-12 | 1999-07-07 | 美国拜尔公司 | Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate |
| CN1948295A (en) * | 2005-10-11 | 2007-04-18 | 四川贝力克生物技术有限责任公司 | Preparation method of 5-(2-phenyl)-2-mercapto-1,3,4-thiadiazole |
| CN102775370A (en) * | 2011-05-11 | 2012-11-14 | 中国科学院海洋研究所 | Thiazole compound, its preparation and application |
| CN103145645A (en) * | 2013-03-18 | 2013-06-12 | 陆宏庆 | Preparation technology of mercapto-5-methyl-1,3,4-thiadiazole |
| CN103360337A (en) * | 2013-07-11 | 2013-10-23 | 浙江海蓝化工有限公司 | Preparation method of 2-sulfydryl-5-methyl-1, 3, 4-thiadiazole |
| CN107721948A (en) * | 2017-11-16 | 2018-02-23 | 江苏绿叶农化有限公司 | A kind of preparation method of flufenacet |
| WO2019234651A1 (en) * | 2018-06-06 | 2019-12-12 | Isagro S.P.A. | Process for the preparation of thiadiazole derivatives |
Non-Patent Citations (3)
| Title |
|---|
| AJOY SAHA ET AL.: "Green Synthesis of 5-Substituted-1,3,4-thiadiazole-2-thiols as New Potent Nitrification Inhibitors", 《J. HETEROCYCLIC CHEM.》 * |
| M OHAMMED SALEH TAWFEK MAKKI ET AL.: "Synthesis of Some More New Sulfur Compounds Bearing Heterocyclic Systems as Biocidal Agents----Part I：Synthetic of 2-Thioxo Thiadiazinone Derivatives", 《JOURNAL OFCHEMISTRY AND CHEMICAL ENGINEERING》 * |
| 姜育田等: "氟噻草胺的合成", 《农药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114380770A (en) * | 2021-12-24 | 2022-04-22 | 山东艾孚特科技有限公司 | Synthesis process of methyl mercapto thiadiazole catalyzed by solid superacid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2546683A1 (en) | Process for producing dichloropropanol from glycerol, the glycerol coming eventually from the conversion of animal fats in the manufacture of biodiesel | |
| CN109721545B (en) | Preparation method of azoxystrobin intermediate | |
| CN107674033B (en) | Production process of 2-methyl-5 nitroimidazole | |
| CN103724327B (en) | High-efficiency and green method for preparing pymetrozine | |
| CN111925340A (en) | Preparation process of methyl mercapto thiadiazole | |
| CN105218472B (en) | A kind of preparation method of triazinone | |
| CN101875671A (en) | Synthesis method of glyphosate | |
| CN111484426A (en) | Method for synthesizing aminoacetonitrile hydrochloride from hydrocyanic acid | |
| CN113773239A (en) | Synthetic method of 1, 3-diaminothiourea | |
| CN106316869A (en) | Synthesis method of beta-alanine methyl ester salt product | |
| CN104327040A (en) | Synthetic method for 2-thiopheneacetic acid | |
| CN103951669B (en) | Synthesis method of Anagliptin key intermediate | |
| CN101875672A (en) | Synthesis method capable of improving yield of glyphosate | |
| CN114044747A (en) | Synthetic method of o-methylthiobenzonitrile | |
| CN110655494A (en) | Novel synthetic method of metribuzin intermediate | |
| CN105254611A (en) | Preparation method for benzothiophene-2-carboxylic acid | |
| CN106316870A (en) | Synthesis method of L-glycine methyl ester salt product | |
| CN110790643A (en) | Method for synthesizing trimethyl orthoformate from methanol hydrochloride and hydrocyanic acid | |
| CN105152984A (en) | Continuous synthetic method of nitroguanidine | |
| CN104513197A (en) | 2-aminonicotinic acid synthetic method | |
| US4988789A (en) | Process for preparing glycine hydrochloride | |
| CN111875510A (en) | Method for preparing aminoacetaldehyde dimethyl acetal | |
| CN100567259C (en) | A kind of method for preparing ethylene sulfite | |
| BR0100689A (en) | Cyclic acid manufacturing | |
| CN103804210B (en) | A kind of purification method of betaine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201113 |
|
| RJ01 | Rejection of invention patent application after publication |